Browse Articles

Discover research articles across all indexed journals

Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy.

Journal of Clinical Oncology Ivan de Kouchkovsky, Moein Moradpour, Li Zhang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.46

46 Background: The prognostic significance of PSMA positron-emission tomography (PET) uptake on prostate cancer (PC) outcomes is not well established. Higher uptake predicts recurrence in men with localized PC, but may be associated with improved survival in pts with mCRPC receiving chemotherapy or radioligand therapy. We sought to evaluate the predictive and prognostic value of baseline PSMA PET uptake in mCRPC pts starting 1L ARSI therapy. Methods: A retrospective analysis of consecutive mCRPC pts who underwent PSMA PET imaging at our institution from 2016 to 2023 was undertaken. Pts were included if a PSMA PET scan performed in the setting of mCRPC showed ≥1 lesion with SUV max ≥3 and 1L ARSI was initiated as the immediate next-line of therapy after scan. PSMA PETs were analyzed and manually segmented by a trained radiologist using MIM Software and SUV threshold of 3; physiologic uptake was removed. SUV max , SUV mean , tumor volume (TV) and total lesion PSMA (TL-PSMA = SUV mean x TV) were obtained for each patient. PSA response on 1L ARSI therapy, PSA progression-free survival (PSA-PFS), time to next treatment (TNT), and overall survival (OS) were retrospectively assessed from start of ARSI. Baseline PSMA PET characteristics were compared across pts with vs without PSA response to 1L ARSI. Time-to-event statistics were performed using the Kaplan-Meier method and Cox proportional hazards model. Statistical significance was declared for p < 0.05. Results: Forty-nine mCRPC pts with PSMA PET imaging performed prior to 1L ARSI (abiraterone in 27, 2 nd generation AR antagonist in 22) were identified. Median SUV max , SUV mean , TV and TL-PSMA were 30.5, 7.2, 22.5 mL and 221.1, respectively. Pts who achieved a greater than ≥90% decline in PSA on ARSI therapy (n=24) had significantly lower SUV max (median 17.7 vs 40.2, p=0.029) and SUV mean (median 6.3 vs 9.9, p=0.017) at baseline. Baseline SUV mean , SUV max , and TV did not predict PSA-PFS, TTNT or OS; however, baseline log10-transformed TL-PSMA was associated with inferior PSA-PFS (HR 1.76, 95% CI 1.07-2.91 p=0.026) on univariate analysis. On Kaplan-Meier analysis, pts in the highest quartile of TL-PSMA had a significantly shorter median OS compared to others (25.3 vs 67.3 months, log-rank p=0.039). Conclusions: In this cohort of mCRPC pts treated with 1L ARSI, those achieving a PSA90 response had significantly lower SUV max and SUV mean on baseline PSMA PET. However, PSMA uptake did not predict longer-term outcomes such as PSA-PFS, TTNT and OS. Pts with higher PSMA-TL had a higher risk of PSA progression and shorter OS. These hypothesis-generating results suggest that although lower PSMA PET uptake may predict initial response to ARSI, tumor burden (PSMA-TL) is a stronger predictor of long-term outcomes. Prospective validation is needed.

National cancer system characteristics and prostate cancer outcomes: A global analysis.

Journal of Clinical Oncology Edward Christopher Christopher Dee, Ranvir Iyengar, Aditya Narayan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.24

24 Background: The number of prostate cancer cases globally is projected to double from 2020 to 2040. However, significant global variation exists in prostate cancer incidence and mortality. A more specific understanding of health system levers specific to prostate cancer may inform health system planning. Therefore, we used global health system data from the World Health Organization (WHO), the World Bank, the Directory of Radiotherapy Centres (DIRAC), the United Nations Development Programme (UNDP), and the International Agency for Research on Cancer (IARC) to evaluate predictors of prostate cancer outcomes globally. Methods: National estimates of age-standardised incidence and mortality rates were obtained from the IARC 2022 database for male patients with prostate cancer of all ages (available for 185 countries). Mortality-to-incidence ratio (MIR), a proxy for survival, was calculated for each country. The following were taken from the World Bank: health spending as a percent of gross domestic product (GDP, 2021), physicians per 1000 population (2016-2021), nurses and midwives per 1000 population (2016-2021), surgical workforce per 1000 population (2013-2018), and GDP per capita. Universal healthcare (UHC index) and availability of pathology services were taken from the WHO. The gender inequality index (GII) and human development index (HDI) were taken from UNDP. Number of radiotherapy centers from DIRAC was used to derive number of radiotherapy centers per 1000 people. The association between prostate MIR and each of the ten metrics was evaluated using univariable linear models; Bonferroni corrected P<0.005 associations were included in the multivariable regression (MVA). We then assessed multicollinearity through variation inflation factor (VIF) analysis (VIF>10 excluded). α=0.10 defined statistical significance in the MVA. R2 evaluated goodness of fit. Results: Data availability ranged from 144 (77.8%, surgical workforce per 1000 population known) to 185 (100%, GDP per capita, RT centers per 1000 population). On univariable analysis, each of the ten metrics were significantly associated with MIR of prostate cancer (<0.001 for all). In MVA (N=123), VIF for HDI was 19.06. The final model (N=123 countries) with nine metrics had an R2 of 0.84. Therefore, the following variables were associated with lower (improved) MIR for prostate cancer: 1) surgical workforce per 1000 population, 2) UHC index, 3) radiotherapy centers per 1000 population, 4) GDP per capita. MIR plotted individually against these four metrics illustrates these associations. Conclusions: Analysis of global data and health-system metrics suggest that surgical workforce, availability of radiotherapy centers, degree of UHC, and GDP per capita are associated with improved prostate cancer outcomes. In leveraging individual countries’ health systems as data points, these findings may guide health system planning and prioritization.

Final overall survival of ARIES trial evaluating first line avelumab monotherapy for patients with advanced urothelial cancer (aUC) unfit for cisplatin and outcome analysis based on baseline characteristics.

Journal of Clinical Oncology Denis Occhipinti, Chiara Ciccarese, Matteo Santoni et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.797

797 Background: ARIES trial evaluated avelumab monotherapy in PD-L1+ve aUC patients (pts) not eligible to cisplatin-based chemotherapy, reaching its primary endpoint (Iacovelli R et al. ASCO-GU 2022). Treatment landscape for aUC has changed since enfortumab-vedotin and pembrolizumab (EV+P) has become the new standard for platinum-eligible pts reporting also a mPFS of 10.6 mos and 1-y OS rate of about 80% in cisplatin ineligible (carboplatin-eligible) pts. Unfortunately, up to 20% of pts are not eligible to platinum-based chemotherapy (PBC) and guidelines continue to recommend immunotherapy alone. Methods: Pts with PDL1+ve aUC and not eligible for cisplatin-based chemotherapy were enrolled and treated with avelumab until progression of disease. Here we reported the final OS, and we evaluated the baseline differences between pts with longer PFS compared to those who immediately progressed. Baseline characteristic included in this analysis were sites of metastases, performance status, body mass index (BMI), haematological values and the Neutrophils-to-Lymphocytes Ratio (NLR). Results: 71 pts were enrolled, the median age was 75 years (range 38 – 88); bladder cancer was the primary tumour in 73.2% of cases, 25.3% had liver metastases, 31% had ECOG=2 and 31% had renal function <50ml/min. After a median FU of 52 mos, the median OS was 10.3 mos (95%CI 5.3 – 15.3) and the median PFS was 2.1 mos (95%CI 1.8 – 2.4). 26 pts (37%) received subsequent therapies, with gem+carbo as most frequently used (15 pts, 21%). A total of 18 pts (25%) had a PFS ≥9 mos while 44 (62%) had a PFS ≤3 mos. Significant differences between these two groups were the presence of liver mets (11% vs. 36%; p=0.047), the presence of node only disease (39% vs 5%; p<0.001) and the rate of pts with NLR>4 (22% vs. 61%; p=0.005). At multivariable analysis only NLR>4 and liver mets were confirmed to be independent prognostic factors. The 27 pts (38%) without liver mets and with NLR>4 had significantly (p=0.001) prolonged mPFS (7.7 vs. 1.9 mos), mOS (20.4 vs. 5.7 mos), and 1y OS rate (67% vs. 32%). Conclusions: ARIES trial confirmed the activity of avelumab in cisplatin-ineligible aUC pts including those not eligible to PBC. This analysis also identified the absence of liver mets and low values of NRL as potential markers of significant benefit from immunotherapy alone. This evidence can be used for a personalized approach in the evolving treatment landscape of aUC. Clinical trial information: NCT03891238 .

Equal-depth sequencing of white blood cells (WBC) and plasma from prostate cancer (PCa) liquid biopsies (LBx) and association with clonal hematopoiesis (CH) confounders in clinically relevant genes.

Journal of Clinical Oncology Emmanuel S. Antonarakis, Catherine Handy Marshall, Derek W Brown et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.221

221 Background: CH results from fitness-enhancing mutations in hematopoietic stem cells that accumulate with age. Deep sequencing of LBx, a standard of care for guiding therapy selection in advanced PCa, can be confounded by sensitive detection of variants (vars) arising from both ctDNA and CH-derived DNA. Here we report the prevalence of CH vars in PCa and other cancers and describe an algorithmic method for accurately distinguishing CH from tumor signal, even at low variant allele frequencies (VAF). Methods: Plasma cell-free DNA from 1813 patients with cancer (n = 270 PCa) was sequenced using FoundationOneLiquid CDx (F1LCDx) in a CLIA lab setting. In parallel, DNA from buffy coats was extracted, sheared, and sequenced on F1LCDx to identical depth, to establish ground truth for CH var identity. This cohort was used to train a machine learning variant origin prediction (VOP) model incorporating fragmentomics and other sequencing features to assign probabilities of origin (germline, tumor, or CH) to all short variants across the 324 genes baited on the assay. Only pathogenic vars were considered. Results: 1247/1813 (69%) of LBx detected ≥1 CH var, including 209/270 (77%) of PCa LBx (mean 1.8 vars/sample). CH contributed confounding vars in clinically relevant genes including CHEK2, ATM, BRAF, TP53, and BRCA2 in 90/270 (33%) of PCa LBx (Table). Median VAF of CH vars in these genes was 0.3% in LBx and 0.7% in WBC. CH vars enriched in PCa vs other cancers were: TET2 (23.0% of PCa LBx vs 13.6% of non-PCa), ASXL1 (14.4% vs 7.5%), SF3B1 (7.0 vs 2.3%), and TERT promoter (5.2% vs 1.3%), FDR <0.05 for all. In the pan-cancer cohort, the VOP algorithm identified CH vars with 95.2% (2613/2745) sensitivity, 94.1% (3741/3975) specificity, and 91.8% (2613/2847) positive predictive value (PPV). For CH vars with VAF<1%, VOP had 95.0% (1622/1707) sensitivity, 1021/1169 (87.3%) specificity, and 91.6% (1622/1770) PPV. Conclusions: Equal-depth DNA sequencing of plasma and matched WBC reveals higher CH prevalence in LBx than previously reported: 77% of PCa LBx with a CH var, including 33% with a CH var in clinically relevant genes . Many potentially actionable vars have low VAF in LBx, and filtering CH via shallower depth WBC sequencing than that of LBx risks leaving low VAF CH vars to be mistaken for tumor vars. Equal-depth WBC sequencing or an algorithmic method validated using equal-depth WBC sequencing is required for accurate identification of low VAF CH confounders in LBx. Percentages of LBx with only CH vars/total LBx with vars detected in genes clinically relevant in PCa. Gene PCa Pan-cancer CHEK2 19/25 (76%) 143/168 (85%) ATM 18/29 (62%) 156/227 (69%) BRAF 2/5 (40%) 10/48 (21%) TP53 46/120 (38%) 235/996 (24%) BRCA2 2/12 (17%) 3/37 (8%) PALB2 0/3 (0%) 4/17 (24%) BRCA1 0/2 (0%) 5/28 (18%) CDK12 0/7 (0%) 3/17 (18%)

Efficacy and safety of organoid-based drug sensitivity screening to guide the treatment of mCRPC patients progressed after first-line treatment.

Journal of Clinical Oncology Diwei Zhao, Junliang Zhao, Yuanwei Li et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps278

TPS278 Background: Treatment for metastatic castration-resistant prostate cancer (mCRPC) patients progress after first-line therapy remains challenging due to limited options and heterogeneous response. Organoid-based drug sensitivity screening offers an innovative approach by simulating the tumor microenvironment in vitro, potentially allowing for personalized treatment strategies based on individual tumor responses to various drugs. This study aims to assess the efficacy and safety of using organoid-based drug sensitivity screening to guide treatment decisions in mCRPC patients. Methods: This is a prospective, open-label, single-arm observational study designed to recruit 30 mCRPC patients with bone metastases who have progressed after first-line therapy. Residual tissue from biopsies of bone metastatic lesions will be used to culture organoids for drug sensitivity screening. Screening regimens include at least Olaparib, Docetaxel or platinum-based chemotherapy, and Abiraterone plus Niraparib, as recommended by current guidelines. Additionally, 141 other drugs from a previously established library are available for screening, based on investigator and patient preferences. The treatment regimen will be selected based on the agent that demonstrates the highest sensitivity in the screening process. The primary endpoint is PSA response rate, defined as a 50% decrease in PSA levels from baseline. Secondary endpoints include radiologic progression-free survival (rPFS), objective response rate (ORR), duration of response (DOR), and overall survival (OS). Patient recruitment is ongoing at Sun Yat-sen University Cancer Center, with 5 patients (5/30, 16.7%) enrolled as of September 3, 2024. Data analysis is expected to begin in 2025, following the completion of recruitment. Clinical trial information: NCT06529549 .

Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of advanced prostate cancer: Data from a 52-week clinical trial.

Journal of Clinical Oncology Jose De La Cerda, Laurence Belkoff, Kevin Dale Courtney et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.156

156 Background: Relugolix (REL) is the only oral androgen deprivation therapy (ADT) indicated for advanced prostate cancer (aPC). Combining ADT with androgen receptor signaling inhibitors (ARSIs) has shown improved clinical outcomes in hormone-sensitive and castration-resistant PC. This study evaluated the safety and tolerability of REL with the ARSIs abiraterone (ABI) or apalutamide (APA). Methods: In this open-label, two-part study, patients (pts) with aPC, including ADT-experienced, were treated for 52 weeks (wks). In Part 1, pts received REL 120 mg qd + ABI 1000 mg qd + either prednisone 5 mg qd or bid or methylprednisolone 4 mg bid. In Part 2, pts received REL 240 mg qd + APA 240 mg qd. Pts with metastatic castration-sensitive PC were eligible for Part 1 & 2. Castration-resistant pts were eligible for Part 1 with metastatic and for Part 2 with non-metastatic PC. The primary objective was to assess safety and tolerability. Testosterone (baseline, wk 2, 4, 12) and PSA (baseline, wk 12) levels were also evaluated. REL, APA, and N-desmethyl APA concentrations were determined at baseline, wks 2, 4, 8, and 12 in Part 2. REL adherence was measured by pill count. Results: Twenty-four pts were enrolled in each part, with 21 and 20 completing Part 1 & 2, respectively. Most pts were white with a mean age of 71 and 69 years in Part 1 & 2, respectively. Mean REL treatment adherence was > 97% in the study. The majority of reported adverse events (AEs) were mild (grade 1 or 2) in Part 1 & 2. The most commonly reported AE was hypertension in Part 1 and rash in Part 2. No relevant post-treatment changes in laboratory, ECG, or vital sign parameters were noted. Mean testosterone levels were maintained below castration level (50 ng/mL) through the 12-wk treatment. Mean (SD) and median PSA levels were 28.1 (127.1) and 0.04 ng/mL (1 pt with 611 ng/mL) in Part 1 and 0.2 (0.3) and 0.04 in Part 2 at wk 12, respectively. REL, APA, and N-desmethyl APA concentrations were stable over 12 wks indicating steady-state conditions. Conclusions: REL used in combination with ABI or APA showed safety profiles consistent with individual drugs over 52 wks. REL levels were stable, and testosterone was sustained below castration level. These findings support the safety and tolerability of REL combination therapy with ABI or APA for aPC. Clinical trial information: NCT04666129 . Part 1 (N=24) Part 2 (N=24) Age 1 (years), mean (SD) 71 ± 7 69 ± 7 Race 1 , White, n (%) 19 (79) 16 (67) Adherence 2 , mean (SD) 98.5% (3.2) 97.8% (8.0) Any TEAE, n (%) 22 (91.7) 21 (87.5) Most common TEAE 2 , n (%) Hypertension, 6 (25.0) Rash 5 (20.8) Any Serious TEAE 2 , n (%) 3 (12.5) 1 (4.2) Testosterone 3 (ng/dL), mean (SD) 2.9 (6.9) 15.3 (12.4) Relugolix 4 (ng/dL), mean (SD) - 10.9 (10.7)/11.1 (9.7) Apalutamide; N-desmethyl apalutamide 4 (ng/dL), mean (SD) - 4088.3 (1046.8)/3666.4 (1154.0);4767.4 (1133.3)/4717.5 (1362.7) 1 Baseline; 2 Week 52; 3 Week 12; 4 Weeks 2/12. TEAE = treatment emergent adverse events.

Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.

Journal of Clinical Oncology Toni K. Choueiri, Jae Lyun Lee, Jaime R. Merchan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.441

441 Background: ccRCC, the most common histologic subtype of renal cancer, is universally associated with dysregulation of the VHL pathway, leading to HIF-2α accumulation and upregulation of multiple oncogenic pathways. Cas is an orally bioavailable, small-molecule HIF-2α inhibitor that potently inhibits transcription of HIF-2α-dependent genes. Methods: ARC-20 (NCT05536141) is a phase 1, open-label study evaluating Cas monotherapy in pts (age ≥18) with ccRCC who are HIF-2α inhibitor naïve and previously treated with anti-PD-(L)1 and VEGFR-TKI therapies. Trial endpoints included incidence of treatment-emergent adverse events (TEAES) and objective response rate (ORR) by RECIST v1.1. Results: Prior to dose expansion, dose escalation occurred in 4 pts with ccRCC (3 pts 50 mg BID; 1 pt 50 mg QD) of which 2 pts had SD,1 pt had PR, and 2 remain on study as of 30Aug2024. In dose expansion, 64 pts received Cas (33 pts 50 mg BID, 31 pts 50 mg QD). Median prior lines of treatment were 3 (range 1–7) across doses. Median follow-up (months, range) was 11 (3–15+) and 8 (4–10+) for 50 mg BID and 50 mg QD, respectively. Cas-related grade ≥3 TEAE occurred in 42% (n=14) and 36% (n=11) of pts, respectively. Notably 36% of pts experienced grade 3 anemia, regardless of dose, and grade 3 hypoxia occurred in 9% and 6% of pts, respectively. No grade ≥4 TEAEs occurred. Activity was seen across all IMDC risk groups, regardless of dose, and in pts with or without prior mTOR inhibitor (Table). Cas 100 mg demonstrated optimal sustained EPO reduction. Biomarker analysis, including HIF-1α and HIF-2α immunohistochemistry, mutational status of VHL/ccRCC relevant genes, predictive transcriptomic signatures and efficacy data with longer follow up will be presented. Conclusions: In heavily pretreated pts with ccRCC, Cas monotherapy was well tolerated with promising early clinical activity across IMDC risk groups. Cas 100 mg QD will be combined with VEGFR-TKI (cabozantinib) in the phase 3 PEAK-1 trial and immunotherapy (volrustomig) in a separate upcoming first-line trial. Clinical trial information: NCT05536141 . Cas50 mg BID(n = 32 a ) Cas50 mg QD(n = 28 a ) IDMC Favorable(n=15) IMDC intermediate/ poor/unknown(n=45) Without prior mTOR inhibitor treatment (n=51) With prior mTOR inhibitor treatment (n=9) Unconfirmed ORR, % (n) (95% CI) 34 (11 b )(19, 53) 25 (7)(11, 45) 40 (6)(16, 68) 27 (12)(15, 42) 31 (16)(19, 46) 22 (2)(3, 60) Confirmed ORR, % (n) (95% CI) 25 (8)(11, 43) 21 (6)(8, 41) 33 (5)(12, 62) 20 (9)(10, 35) 26 (13)(14, 40) 1 (11)(<1, 48) Disease control rate, % (95% CI) 81(64, 93) 86(67, 96) 93(68, 100) 80(65, 90) 82(69, 92) 89(52, 100) a Efficacy-evaluable pts: all pts who had measurable disease at BL, received ≥1 dose and had ≥1 post-BL efficacy assessment, or who discontinued study treatment due to progression or death. Disease control rate: ORR+SD. b Includes 1 pt who achieved PR after data cut-off.

Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients.

Journal of Clinical Oncology Ping Du, Jiemin Liao, Angela Watkins et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.69

69 Background: Circulating tumor DNA (ctDNA) from blood-based liquid biopsies is emerging as a promising biomarker with potential prognostic and predictive value for managing patients across tumor types and therapeutic areas. Yet data and understanding of how ctDNA might be used as a prognostic biomarker in prostate cancer (PC) are limited. This study used real-world data (RWD) to evaluate the association between ctDNA burden and clinical characteristics and outcomes in PC. Methods: Prostate cancer patients were identified from the Guardant INFORM real-world clinical-genomic database, which connects ctDNA results obtained through the plasma-based next-generation sequencing Guardant360 assay (G360) to de-identified claims data. U.S. PC patients who underwent a G360 test between June 2014 and June 2023 were included. A 6-month baseline period prior to the first G360 test (index) was used to gather clinical information on these patients. ctDNA burden for each patient was defined as the maximum variant allele frequency (MVAF) of all somatic variants. The median MVAF across all samples was used to classify patients into high or low ctDNA burden groups. The association between ctDNA and real-world overall survival (rwOS) was assessed using log rank tests and multivariable Cox proportional hazards models adjusted for age, race/ethnicity, year of test, comorbidity indices, metastasis status, PC clinical state, and presence of androgen receptor ligand binding domain (AR LBD) mutations. Results: 16,757 PC patients were identified, of which, 13% had undetectable ctDNA burden. Using a median MVAF cut-off of 1.9% (range: 0.01% to 96.4%), 7,216 had low ctDNA burden and 7,330 had high ctDNA burden. Among patients with detectable ctDNA, higher ctDNA burden was observed in patients with metastatic castration resistant prostate cancer (N=5,996, median=2.4%), smokers (N=2,580, median=2.5%), with higher comorbidity burden (N=3,336, median=3.0%), and those AR LBD mutations (N=2,624, median=8.6%). Patients with high ctDNA burden showed significantly shorter rwOS after the index date (16.4 months [95%CI: 15.8-17.0]) than low and undetectable ctDNA burden groups (34.8 [95%CI: 32.8-37.0] and 53.1 months [95%CI: 48.6-65.9], respectively). Multivariable Cox models showed similar results (high ctDNA vs undetectable ctDNA hazard ratio [HR] = 3.16; low ctDNA vs undetectable ctDNA HR = 1.45; high ctDNA vs low ctDNA HR = 2.18). Conclusions: In this real-world study with large PC population, ctDNA burden varied by severity of disease and was negatively associated with overall survival after adjustment for other prognostic features. Our study adds to the body of evidence suggesting the utility of ctDNA as a potential prognostic biomarker in PC patients to monitor disease progression and patient outcomes in routine clinical practice.

Association between radiation therapy to the recurrence sites and oncological outcomes in patients who experienced local recurrence and/or pelvic lymph node metastases after radical cystectomy: A multicenter retrospective study.

Journal of Clinical Oncology Naoki Fujita, Shogo Hosogoe, Toshikazu Tanaka et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.788

788 Background: Local recurrence and/or pelvic lymph node metastases after radical cystectomy (RC) are often observed in patients with muscle-invasive bladder cancer (MIBC). Although chemotherapy and immune checkpoint inhibitors are the main treatment strategies in such patients, radiation therapy (RT) to the recurrence sites might be one of the treatment options. However, its effects on oncological outcomes remain unclear. Methods: This multi-institutional retrospective study included 106 patients who experienced local recurrence and/or pelvic lymph node metastases without distant metastases after RC. Patients were divided into two groups: patients who were treated with RT to the recurrence sites (RT group) and without (non-RT group). Multivariable Cox-proportional hazards regression analyses were performed to evaluate the effects of RT on cancer-specific survival (CSS) and overall survival (OS) after recurrence. Results: The median age at recurrence was 72 years, and the median follow-up period after recurrence was 13 months. Of the 106 patients, 65 (61%) received neoadjuvant chemotherapy (NAC) and 30 (28%) were treated with RT after recurrence. CSS and OS were not significantly different between the two groups ( P = 0.569 and P = 0.456, respectively). In univariable analyses, NAC, pure urothelial carcinoma, tumor grade, and lymphovascular invasion were significantly associated with CSS. Similarly, NAC, pure urothelial carcinoma, tumor grade, lymphovascular invasion, and pathological lymph node involvement were significantly associated with OS. After adjustment for these confounding variables, RT to recurrence sites was not significantly associated with prolonged CSS and OS (Table). Conclusions: RT to recurrence sites might have no effects on oncological outcomes in patients who experienced local recurrence and/or pelvic lymph node metastases after RC. Multivariable analyses for CSS and OS. CSS Factor P value HR 95% CI NAC Received 0.080 0.649 0.400–1.053 Pure urothelial carcinoma Positive 0.059 0.577 0.326–1.022 Tumor grade Grade 3 0.644 1.167 0.606–2.247 LVI Positive 0.003 2.407 1.353–4.283 Radiation therapy Positive 0.244 0.735 0.438–1.234 OS Factor P value HR 95% CI NAC Received 0.030 0.552 0.323–0.944 Pure urothelial carcinoma Positive 0.113 0.574 0.289–1.141 Tumor grade Grade 3 0.694 0.868 0.428–1.759 LVI Positive 0.005 2.438 1.305–4.556 Pathological N stage ≥ pN1 0.328 1.372 0.728–2.584 Radiation therapy Positive 0.161 0.652 0.359–1.186

Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Georges Gebrael, Yeonjung Jo, Chadi Hage Chehade et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.75

75 Background: The Rx landscape of pts with mCRPC has recently evolved with the approval of lutetium-177-PSMA-617 (Lu-177) and poly(ADP) ribose polymerase inhibitors (PARPi) either as single agents or as combinations with an androgen receptor pathway inhibitor (ARPI) [PMID: 37442702]. However, real-world data on the uptake of these agents are lacking. Herein, we sought to assess the Rx patterns and attrition rates of pts with mCRPC in the era of newly approved therapies. Methods: The de-identified nationwide Flatiron Health Electronic-Health Record (EHR)-derived database was used to extract pt-level data. Eligibility criteria: diagnosis of mCRPC and Rx line (L) information. The data cut-off date was 5/31/2024. Rx patterns in each line of therapies were summarized using frequency and percentages. All analysis was done using R version 4.2.3. Results: Of the overall cohort of 24,105 pts with metastatic prostate cancer, 12,333 pts diagnosed with mCRPC between 1/1/2013 and 5/9/2024 met the eligibility criteria and were included. Rx trends are summarized (Table). Of pts receiving 1L Rx, 61% of pts received 2L therapy, and 35% received 3L therapy. Androgen receptor pathway inhibitor (ARPI) was the most common Rx in the 1L setting (73.7%), followed by taxane (10%) and sipuleucel-T (3.8%). In 2L, ARPI was again the most frequent Rx (46.8%), followed by taxane (23.6%). In 3L, taxane became the most frequent Rx (35.4%), followed by ARPI (26.2%) and radium-223 (4.9%). Rx trends per year will be presented in the meeting. Conclusions: In the current era,a high proportion of pts with mCRPC receiving 1L Rx do not receive a subsequent line of Rx (39% of pts do not receive 2L, and 65% do not receive 3L Rx). ARPIs and taxanes remain the most frequently used Rx options in most L of therapy. These findings highlight the need for better tolerated Rx, therapies with a novel mechanism of action, and improved access to care for our pts. Rx trends per year will be presented in the meeting. Rx patterns in pts with mCRPC. Rx 1L, n (%)N = 12,333 2L, n (%)N = 7475 3L, n (%)N = 4316 4L, n (%)N = 2339 5L, n (%)N = 1225 ARPI 9085 (73.7) 3503 (46.8) 1130 (26.2) 356 (15.2) 157 (12.8) PARPi-based therapies 93 (0.8) 185 (2.5) 142 (3.3) 98 (4.2) 47 (3.9) Platinum-based therapy 127 (1) 216 (2.9) 198 (4.6) 148 (6.3) 130 (10.6) Lu-177-based therapies 50 (0.4) 109 (1.5) 169 (3.9) 143 (6.3) 103 (8.4) Radium-223 183 (1.5) 241 (3.2) 213 (4.9) 125 (5.3) 79 (6.4) Sipuleucel-T 474 (3.8) 94 (1.3) 53 (1.2) 18 (0.8) 8 (0.7) Taxane 1240 (10) 1763 (23.6) 1526 (35.4) 935 (40) 393 (32) Pembrolizumab 24 (0.2) 41 (0.5) 36 (0.8) 27 (1.2) 29 (2.4) Other*/not-applicable** 665 (5.4)/392 (3.2) 1000 (13.4)/323 (4.3) 602 (14)/247 (5.7) 320 (13.7)/169 (7.2) 162 (13.3)/117 (9.5) *Includes drugs approved for mCRPC in combination with unapproved agents or clinical trial drugs. **Includes agents not approved for prostate cancer.

Evaluation of ctDNA alterations in lethal mCRPC.

Journal of Clinical Oncology Minqi Huang, Nicholas Habibian, Tivoli Nguyen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.245

245 Background: Circulating tumor DNA (ctDNA) can be used as a prognostic biomarker in mCRPC patients, with changes in ctDNA providing insight into patient survival. In this study, we evaluate the ctDNA landscape of patients with mCRPC prior to their death. Methods: A retrospective clinical data review, 2015-2024, was conducted at Tulane Cancer Center to identify mCRPC patients who underwent ctDNA testing prior to death. All ctDNA data were obtained through a multi-gene cancer panel via the Guardant 360 assay (70-83 genes). Lethal mCRPC was defined as patients who underwent ctDNA testing ≤3 months prior to death. A matched control group (CTRL) was defined as mCRPC patients with ctDNA collection ≥2 years prior to death or most recent follow-up. Statistical analyses were performed using Pearson Chi-Square Test or Fisher Exact Test whenever appropriate. Furthermore, survival analysis was conducted using the Kaplan-Meier method. Results: There were 70 patients in lethal mCRPC group and 157 patients in CTRL group. Compared to the CTRL group, in lethal mCRPC, somatic mutations and/or amplifications in BRAF(OR=2.1549, 95% C.I. [1.1136,4.1523], p=0.0298), CCND2 (OR=3.7925, 95% C.I.[1.1937,13.3380], p=0.03326), MYC (OR=2.6332, 95%C.I. [1.4158, 4.9120], p=0.0029), PDGFRA (OR=2.5235, 95% C.I. [1.1438, 5.5793], p=0.0291), and PIK3CA (OR=2.0328, 95% C.I. [1.1098, 3.7166], p=0.02846) were significantly more frequent. Additionally, lethal mCRPC patients were more likely to have missense (OR=4.3194, 95% C.I. [1.443456,19.3338], p=0.01687) and nonsense (OR=1.9364, 95% C.I. [1.06091,3.5250], p=0.04112) mutations at the end-of-life. Patients with a higher allelic fraction (≥0.6%) of TP53 alterations had a shorter median survival (p-value= 0.034). Conclusions: ctDNA mutations and/or amplifications in BRAF, CCND2, MYC, PDGFRA, and PIK3CA were more frequently detected in lethal mCRPC compared to matched CTRLs. Additionally, mCRPC patients with a lethal phenotype were more likely to have missense and nonsense mutations compared to the CTRL group. CtDNA assessment of copy number alterations was limited to amplifications only; additionally, with this assay, distinguishing between gene level and large scale chromosomal amplification is not assessable. Though this study is limited to a single-institution with retrospective analyses of clinical testing, understanding the somatic landscape of lethal mCRPC is critical for development of new biomarkers, strategies and ultimately druggable targets.

<sup>68</sup> Ga-FAPI-46 PET/CT for cancer imaging: Results of a single-center, prospective, interventional, single-arm clinical trial.

Journal of Clinical Oncology Kim M. Pabst, Timo Bartel, Patrick Sandach et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.457

457 Background: Fibroblast activation protein (FAP) is highly expressed on tumor-associated fibroblasts. FAP-directed radioligand positron emission tomography ( 68 Ga-FAPI-46 PET) is a novel tool for cancer imaging. However, its diagnostic performance, especially in genitourinary (GU) cancers, is still unclear. Here, we aim to compare diagnostic performance of 68 Ga-FAPI-46 and 18 F-FDG PET, validated by histopathology. Methods: Patients (pts) at initial staging/restaging with (a) proven or suspected malignancy, (b) any tumor diameter &gt; 1 cm, (c) planned or performed biopsy/surgery within 8 weeks prior to or after 68 Ga-FAPI-46 PET, and (d) no prior external beam radiation or systemic tumor therapy within 1 month underwent 68 Ga-FAPI-46 and clinical 18 F-FDG PET on subsequent days. For comparison, patient-based and region-based (local, nodal, distant organ or soft tissue, bone) image analysis was performed by three blinded nuclear medicine physicians, separate for each PET modality. Positive predictive value (PPV) and sensitivity (SE) were evaluated based on histopathologic results, and compared in the subgroups of GU cancers, sarcoma, and others. Inter-reader reproducibility was assessed using Fleiss‘ kappa. Results: A total of n=158 pts (median age: 62 years, male/female: n=101 (63.9%)/57 (36.1%)) were enrolled. 155 (98.1%)/152 (96.2%) pts underwent 68 Ga-FAPI-46/ 18 F-FDG PET/CT. Histopathologic validation was available in n=145 (91.8%) pts. N=54 (34.2%)/28 (17.7%)/76 (48.1%) pts were diagnosed with GU cancers/sarcoma/others. Patient-based PPV/SE for 68 Ga-FAPI-46 ( 18 F-FDG) PET were 94/72% (97/71%) for GU cancers, 100/96% (100/96%) for sarcoma, and 100/91% (100/88%) for others. Region-based PPV/SE for 68 Ga-FAPI-46 ( 18 F-FDG) PET were 93/71% (97/70%) for GU cancers, 100/94% (97/90%) for sarcoma, and 99/90% (93/85%) for others. Patient-based inter-reader reproducibility for 68 Ga-FAPI-46 ( 18 F-FDG) PET was 0.71 (0.43) for GU cancers, 1.0 (0.21) for sarcoma, and 0.6 (0.53) for others. Conclusions: 68 Ga-FAPI-46 and 18 F-FDG PET demonstrate similar accuracy for tumor detection and localization of GU cancers. However, inter-reader reproducibility was superior for 68 Ga-FAPI-46 (substantial agreement) compared to 18 F-FDG PET (moderate agreement). Clinical trial information: NCT05160051 . Patient characteristics. All patients n=158 All regions n=186 Diagnosis n (pts) % (pts) n (regions) % (regions) Genitourinary CancersRenal cell carcinomaUrothelial carcinomaProstate cancerSeminomaOthers 54 3314322 34.2 20.98.91.91.31.3 63 3816414 33.9 20.48.62.20.52.2 Sarcoma 28 17.7 32 17.2 Others* 76 48.1 91 48.9 *Including breast cancer, cholangiocarcinoma, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, lymphoma, multiple myeloma, neuroendocrine, NSCLC, pancreatic cancer, thyroid cancer, unknown primary, others.

Feasibility of enriched amplicon circulating tumor DNA sequencing to detect minimal residual disease (MRD) after prostatectomy in localized prostate cancer.

Journal of Clinical Oncology Peter D. Zang, Daniel Lama, Ziyi Huang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.402

402 Background: Nearly one third of men with prostate cancer experience relapse after radical prostatectomy, often despite achieving undetectable PSA nadir. An assay to detect minimal residual disease would be valuable to identify patients who could benefit from adjuvant therapy. Methods: Eligible patients had biopsy proven prostate cancer and planned to undergo prostatectomy for definitive therapy. Blood was drawn at pre-specified timepoints (TP) including prior to prostatectomy (TP1), on the day after surgery or at the 1-week post-op catheter removal visit (TP2), and at 1-month post-op with no interval treatment (TP3). We performed tumor-guided plasma DNA analysis using a novel method based on single-stranded adapter ligation, incorporation of unique molecular identifiers (UMIs), targeted PCR, normalization of amplicons using hybrid-capture, and targeted sequencing. Using tumor and germline exome sequencing, we designed and validated multiplexed assays to target somatic founder mutations. We prepared targeted sequencing libraries using a median of 6.7 ng input plasma DNA. Results: 11 patients were enrolled after IRB approval. 1 (9.09%) had grade group 2, 1 (9.09%) grade group 3, 5 (45.45%) grade group 4, 4 (36.36%) grade group 5 disease. Median PSA pre-op was 9.3 ng/mL (range: 1.7 – 21.47). Tumor DNA sequencing was successful and targeted assays were generated for all patients (11/11). Median number of targets tested was 20 (range 4 to 88). We analyzed 31 plasma DNA samples obtained from 11 patients. Median on-target rate in plasma DNA was 90.5% (range 76.0% to 96.3%). Prior to surgery (TP1), 5/11 (45%) patients had detectable ctDNA at a median tumor fraction of 0.077% (range: 0.006% to 3.4%). At post-op TP (TP2), the ctDNA was detectable in 7/11 patients (64%) at a median tumor fraction of 0.024% (range: 0.004% to 3.1%). Detectable ctDNA was observed at 1 month (TP3) in 5/8 patients (62.5%) at a median tumor fraction of 0.022% (range 0.010% to 0.037%). For an exploratory analysis, we examined whether persistent ctDNA detection at the 1 month TP3 was associated with later relapse. Of the 5 patients with PSA relapse, 3 (60%) of patients had detectable residual ctDNA at TP3 with median follow up time of 61.75 months. Conclusions: Localized prostate cancer has been noted to have low tumor shed, limiting meaningful ctDNA detection rates with prior assays (Hennigan 2019). Our results show promising feasibility of a novel tumor-informed ctDNA assay in this setting. In addition, there was preliminary evidence of residual ctDNA detection predicting relapse.

Use of integrated multi-omics analysis to analyze prognostic molecular subtype in collecting duct carcinoma.

Journal of Clinical Oncology Xiaowen Wu, Yiqiang Liu, Yu Fan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.585

585 Background: Collecting duct carcinoma (CDC) originates from the principal cells of the collecting ducts in the renal medulla and accounts for less than 2% of all renal cell carcinomas (RCCs). Due to its low incidence, the transcriptomic features and molecular subtypes of CDC have only been described in small-sample studies. This study employs a multi-omics approach to investigate CDC, aiming to deepen our understanding of CDC and provide some references for future treatment options. Methods: A total of 103 tumor samples and 15 paired adjacent non-tumor samples underwent whole transcriptome sequencing. Clinical pathological characteristics, treatments, and prognostic information were collected for all patients. Molecular typing of CDC was performed using Non-negative Matrix Factorization. The clinical and biological characteristics of each subtype were analyzed. Tissues from different NMF classifications were collected for single-cell sequencing to compare the biological characteristics. To enhance clinical accessibility, plasma was analyzed by LC-MS/MS and correlated with RNAseq data to identify representative plasma biomarkers for different NMF subtypes. Results: Compared to normal tissue, CDC exhibited significant differences in various biological functions including mechanisms and regulation of ion and substance transport across cellular membranes, as well as pathways such as proximal tubule bicarbonate reclamation, aldosterone-regulated sodium reabsorption and protein digestion. Tumor samples were classified into two transcriptional subtypes through machine learning: NMF1 and NMF2. NMF1 subtype had a significantly longer overall survival compared to those with the NMF2 subtype (median OS of 7.06 months vs 2.04 months, P =0.014). The infiltration proportions of T cells, CD8+ T cells, cytotoxic lymphocytes, endothelial cells, myeloid dendritic cells, NK cells, and neutrophils were all higher in NMF1 tumor tissues compared to NMF2, while the proportions of fibroblasts and monocytic lineage were lower in NMF1. These immune infiltration results were further validated by single-cell sequencing analysis. Using Lasso regression combined with survival data, we identified characteristic gene sets for each NMF subtype. Further association analysis with plasma LC-MS/MS revealed distinct protein expression profiles for each NMF subtype. These findings suggest that the NMF1 subtype has a relatively better prognosis and a 'hotter' tumor microenvironment, potentially benefiting from immunotherapy and/or anti-angiogenic therapy. Plasma biopsies could serve as a basis for molecular typing. Conclusions: This study is the largest to date to integrate clinical prognostic information in a multi-omics investigation of CDC. It provides critical insights for clinical research on targeted therapies for specific molecular subtypes of CDC.

The significance of androgen receptor signaling pathway in mCRPC patients receiving olaparib monotherapy or combined treatment with abiraterone.

Journal of Clinical Oncology Bin Yang, Li Ding, Baijun Dong et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.197

197 Background: Our previous research confirmed that for metastatic castration-resistant prostate cancer (mCRPC) patients with DNA damage repair (DDR) deficiency who have developed resistance to prior abiraterone, the combination of olaparib and abiraterone improves survival compared to olaparib monotherapy. However, further research is needed to identify subgroups who may benefit from olaparib alone or in combination with abiraterone, and to pinpoint risk factors significantly associated with poor prognosis in these patients. This study aims to explore the value of androgen receptor (AR) variant and androgen receptor activity (AR-A) at the transcriptomic level in evaluating the prognosis of mCRPC patients treated with olaparib alone or in combination with abiraterone. Methods: This study included 142 mCRPC patients who underwent targeted next-generation sequencing. Among them, 73 patients received olaparib monotherapy, while 69 patients received combined therapy. Bulk transcriptome sequencing was performed for 62 patients. Kaplan-Meier analysis was employed to evaluate patients' progression-free survival (PFS) and overall survival (OS). The AR-A score was calculated through a weighted linear sum of nine typical AR transcriptional target genes. Results: The combination of olaparib and abiraterone significantly improved PSA response and survival (PFS and OS) compared to olaparib monotherapy. Among mCRPC patients receiving olaparib monotherapy, those without AR pathogenic variant (AR-PV) had superior PFS and OS compared to those with AR-PV (median PFS: 5 months vs 3 months; median OS: 23 months vs 17 months). At the transcriptome level, for mCRPC patients receiving combined therapy, the average AR-A group exhibited better PFS and OS compared to the lower AR-A group (median PFS: 7 months vs 3 months; median OS: 17 months vs 10 months). Conclusions: For mCRPC patients treated with olaparib monotherapy, the absence of AR-PV can obtain better survival benefits. For patients treated with combined therapy, the average AR-A indicates a better survival benefit. For mCRPC patients with AR-PV or lower AR-A score, large-scale prospective randomized controlled clinical trials are needed to further explore therapy strategies that can improve their prognosis.

Phase 2 randomized study of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis-directed therapy and niraparib/abiraterone acetate plus prednisone (KNIGHTS) trial.

Journal of Clinical Oncology Matthew Pierre Deek, Xiaolei Shi, Noura Radwan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps283

TPS283 Background: Some patients with oligometastases may have the potential for long-term disease-free survival with just aggressive local therapy as shown by randomized trials for total consolidation of macroscopic metastases using metastasis-directed therapy (MDT). Long-term outcomes of pooled STOMP and ORIOLE trials in oligorecurrent metastatic castration-sensitive prostate cancer (omCSPC) demonstrated MDT improved progression free survival. However, men with high-risk mutations, including pathogenic alterations in ATM , BRCA1/2 , Rb1 , and TP53 , did poorly. Additional data suggests men with metastatic castration-resistant prostate cancer and similar mutations are sensitive to PARP inhibition (PARPi) with niraparib. We are launching a first-in-man biomarker-driven trial in omCSPC patients with high-risk mutations to evaluate the efficacy of MDT + androgen deprivation therapy (ADT) versus MDT + ADT + niraparib/abiraterone acetate plus prednisone (nira/AAP). Methods: This study is a multi-site, non-blinded, randomized phase II trial in patients with omCSPC. Men with histologically confirmed (at any site) omCSPC (≤3 metastases on standard imaging or ≤5 on Axumin/Choline/PSMA-PET/CT) and germ-line/somatic high-risk mutations ( TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH ) will be randomized (1:1) to MDT + 6- months ADT versus MDT + 6-months ADT + 6-months nira/AAP. A range of MDT radiation fractionation regimens are permitted. Subjects who meet eligibility criteria and qualify for enrollment will be stratified according to: (i) institution; (ii) conventional/enhanced imaging, (iii) PSADT &lt;6-months, (iv) initial surgery/radiation, and (v) BRCA1/2 status. This study has been IRB approved (NCT06212583). We assume an accrual time of 24 months, with 18 months of additional follow-up time, and will randomize a total of 88 patients (44 patients in each arm). The primary endpoint will be to assess frequency of PSA failure (&gt; 0.2 ng/mL post primary surgery or nadir + 2 post definitive radiation) with testosterone &gt;100 ng/dl at 18-months after randomization (powered for 20% improvement over control arm by Fisher’s exact test). Secondary endpoints will include toxicity, health-related quality of life (HRQoL), time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival, and duration of response. Discovery correlatives associated with clinical outcome will be assessed by collection of including, but not limited to, cell free DNA, circulating-tumor cells, immunologic biomarkers, microbiota and radiomics. Clinical trial information: NCT06212583 .

Homologous recombination repair mutation testing patterns in metastatic castration-resistant prostate cancer: Analysis of real-world data in the United States.

Journal of Clinical Oncology Pedro C. Barata, Suvina Amin, Alexander Niyazov et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.102

102 Background: Homologous recombination repair mutations (HRRms) have predictive/prognostic value in metastatic castration-resistant prostate cancer (mCRPC). While therapies are approved for patients (pts) with HRRm mCRPC, HRRm testing data is limited in the United States (US). This analysis utilized real-world secondary data to assess US HRRm testing patterns in pts with mCRPC. Methods: Data were drawn from the Adelphi Real World Prostate Cancer Disease Specific Programme, a cross-sectional survey with retrospective data collection including medical oncologists (ONC) and urologists (URO) and their mCRPC pts in the US from Nov’22 – Jul'23. ONC/URO reported demographics, disease characteristics, and HRRm testing status for ≥1 of 10 genes of interest ( ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51C ) for eight consecutively seen adult pts. Analyses were descriptive. Logistic regression assessed variables associated with receiving a HRRm test. Results: Overall, 70 ONC/URO reported on 448 pts, of whom 53% received HRRm testing (ONC 57%, URO 39%). Mean (standard deviation) pt age (years) was 69.2 (8.2) for pts who were tested (vs 70.6 [8.3] not tested). HRRm testing occurred in: 73% with a known family history of HRRm-related (prostate/breast/ovarian/pancreatic) cancer (vs 50% without); 53% with visceral metastases (vs 52% without); 61% with an initial localized diagnosis (Dx; vs 48% regional/47% metastatic); 56% of pts with a Gleason score (GS) ≥8 at initial Dx (vs 43% with &lt;8); and 63% with private insurance (vs 48% with public). Metastatic disease at initial Dx (odds ratio [OR] 0.41), no known family history of HRRm-related cancer (OR 0.40), and a GS &lt;8 at initial Dx (OR 0.51) were significantly associated with lower odds of HRRm testing (all p&lt;0.05; Table). Conclusions: In this analysis, nearly half of pts did not receive a HRRm test. As with prior analyses, disparities in testing were evident for pts with a lower GS at initial Dx, metastatic disease at initial Dx and/or those without a family history of cancer, highlighting a need to increase HRRm testing in the US. Association of covariates with odds ratio for HRRm test. Covariate Odds ratio (95% confidence interval) p value Physician specialty: Urologist vs Medical oncologist 0.49 (0.19–1.30) 0.152 Age (years): ≥65 vs &lt;65 0.91 (0.28–2.90) 0.867 Family history of HRRm-related cancer: No history vs Known history 0.40 (0.18–0.89) 0.025* Ethnicity: Non white vs White 0.94 (0.51–1.73) 0.843 Metastatic sites: Visceral metastases vs No visceral metastases 0.67 (0.35–1.29) 0.237 Gleason score: &lt;8 vs ≥8 0.51 (0.27–0.97) 0.042* Initial diagnosis: Regional vs LocalizedMetastatic vs Localized 0.68 (0.28–1.69)0.41 (0.17–1.00) 0.408 0.049* Insurance status: Private vs Public 1.09 (0.47–2.52) 0.844 *Statistical significance ( P &lt;0.05). HRRm, homologous recombination repair mutation.

Improving prostate cancer risk stratification using spatial single-cell tumor profiling.

Journal of Clinical Oncology William S. Chen, Mikhail Dias, Chien-Kuang Cornelia Ding et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.413

413 Background: Effective prostate cancer (PCa) risk stratification is paramount to guide treatment considerations across all stages of PCa. Serum PSA, Gleason score (GS), and bulk-profiling tests (e.g. Decipher) form the cornerstone of risk stratification in clinical practice. New techniques such as Imaging Mass Cytometry (IMC) now enable tumor profiling with unprecedented resolution. We developed a novel IMC assay with the goal of identifying single cell subtypes prognostic of clinical outcomes in localized PCa. Methods: Spatial single-cell expression profiling with IMC was performed on primary PCa tumor biopsies and paired benign prostate samples obtained from patients with localized PCa who subsequently underwent radical prostatectomy. Cell subtypes were defined using the Phenograph cell-clustering approach. Per-sample “cell fraction” (percent abundance) of each cell subtype was defined as cell count of that subtype divided by total number of cells in the sample. Association between cell fraction of each cell subtype and both GS and Canary risk score was assessed using one-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Biochemical progression-free survival (bPFS) and cancer-specific survival (CSS) were prespecified clinical endpoints. Analyses stratified by cell fraction tertiles were performed using the Kaplan-Meier method with Cox proportional hazards testing for significance. All hypothesis tests were performed using a two-tailed significance level of 0.05. Results: Co-expression patterns of 40 selected proteins in 3,429,844 cells comprising 604 biopsy samples obtained from 393 patients were measured. 28 of 393 patients (7%) were assigned a GS of 4+3 or higher. Single-cell clustering analysis revealed 16 distinct prostate, stromal, and immune cell subtypes including androgen-driven (AR+ PSMA+ KLK2+ CD46+) luminal prostate cancer cells (Subtypes 1, 8, 10), basal epithelial cells (Subtype 9), CD8+ T-cells (Subtype 14), CD4+ T-cells (Subtype 15), and antigen-presenting cells (Subtype 12). Subtypes 2, 7, and 9 were enriched in benign and low-risk samples; Subtypes 1, 6 and 12 were enriched in samples with GS of 4+3 or higher (P&lt;0.001) and Canary high-risk ( P &lt;0.01) samples. Patients with tumors enriched for Subtypes 6 and 12 demonstrated shorter bPFS ( P =0.008 and P =0.001 respectively) and shorter CSS ( P =0.02 and P =0.002 respectively) than those with tumors not enriched for these cell subtypes. Multivariable analysis including GS and Canary risk score revealed that Subtype 6 and Subtype 12 cell fraction were both independently prognostic of bPFS and CSS ( P &lt;0.05). Conclusions: In our cohort of men with localized PCa, we identified single-cell features associated with biochemical recurrence and CSS that complement existing risk stratification approaches. Future work includes validation in independent cohorts and further investigation of spatial co-localization patterns between these prognostic cell types and neighboring cells of the tumor microenvironment.

Global real-world patients characteristics, treatment patterns, and impact of BCG shortage in patients with high-risk non-muscle invasive bladder cancer.

Journal of Clinical Oncology Jens Bedke, Anthony Eccleston, Julia Brinkmann et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.717

717 Background: Global guidelines recommend that High Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) patients (pts) receive 1-3 years of Bacillus Calmette-Guérin (BCG) treatment (Tx). This global real-world study aimed to understand pt characteristics, Tx patterns and impact of the BCG shortage in pts with HR NMIBC. Methods: Physicians across EU5 (n=244), the US (n=55), Japan (n=44) and Canada (n=21) were recruited to the Adelphi HR NMIBC Disease Specific Programme: a cross-sectional survey with retrospective data collection extracted from medical record data for their next eight pts with HR NMIBC consecutively consulting with their physician. Tx patterns and characteristics were analysed descriptively. Data was collected from June to December 2023. Results: 364 physicians (55% urologists; 45% medical oncologists) provided data for 1930 pts with an initial diagnosis (IDx) of HR NMIBC. At IDx 73% presented with high grade T1 tumors, 21% had carcinoma in-situ, and 37% had multifocal tumors. The median time between IDx and data collection was 613 days. Tx patterns are described in the table. Of the 1395 pts who received intravesical therapy after IDx, 462 (33%) received induction Tx only, and 875 (63%) received induction followed by maintenance Tx. BCG was most commonly used induction Tx (28%), whilst 5% received intravesical chemo, similarly 56% received BCG maintenance Tx and 7% received chemo. Of those who completed BCG maintenance Tx (n=269) the median (IQR) duration was 336 (180-382) days. Physician reported BCG shortage affected 8% of HR NMIBC pts: 41% received fewer instillations, 37% received lower dosages, and 33% used different strains. Among the 29% of HR NMIBC pts who had ≥1 recurrence the median (IQR) time from IDx to 1 st recurrence was 426 (224-580) days. After 1 st recurrence, 57 pts received partial or radical cystectomies. Physicians surveyed stated that a median 20% of their overall NMIBC caseload were BCG unresponsive and 50% were BCG naïve. 45% of physicians reported having been affected by BCG shortage, ranging from 23% (Japan) to 71% (Canada), 61% reserved BCG for HR pts and 46% used intravesical chemotherapy as an alternative. Conclusions: BCG remains the most frequently prescribed Tx for HR NMIBC pts even though there have been shortage issues and many pts do not receive BCG maintenance. New Tx options that could safely reduce the amount of BCG administered without compromising pts’ outcomes are needed. Tx patterns of pts with HR NMIBC. Tx received After IDx n=1930, n (%) After 1st recurrence n=551, n (%) After 2nd recurrence n=130, n (%) TURBT + intravesical Tx 1209 (63) 194 (35) 40 (31) Other surgery + intravesical Tx 14 (1) 11 (2) 0 (0) Intravesical Tx only 172 (9) 31 (6) 10 (8) TURBT only 327 (17) 162 (29) 43 (33) Other surgery only 13 (1) 9 (2) 3 (2) Radical cystectomy only 0 (0) 44 (8) 6 (4) Other drug Tx ± surgery 88 (4) 41 (7) 9 (7) No Tx 107 (5) 59 (11) 19 (15)

Stage II embryonal predominant NSGCT: Minimizing treatment burden.

Journal of Clinical Oncology Jiping Zeng, Parth Thakker, Timothy A. Masterson et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.634

634 Background: Embryonal carcinoma predominance (ECP) in the orchiectomy specimen is linked to a higher risk of retroperitoneal and systemic relapse. Both chemotherapy and primary retroperitoneal lymph node dissection (RPLND) are recommended options for stage II disease, but the approach that minimizes treatment burden remains unclear. Methods: We queried the Indiana University Testicular Cancer Database to identify patients with non-seminomatous germ cell tumors (NSGCT) and ECP &gt;50% in the orchiectomy specimen, stage II with retroperitoneal adenopathy &lt;5 cm, and normal serum tumor markers. Patients with malignant transformation (n=3) or bilateral cancer (n=3) or receiving 1-2 cycles of BEP after orchiectomy were excluded (n=14). Treatment courses and outcomes were compared. Results: Between 2005 and 2022, 142 patients met the criteria. Of 67 patients who underwent primary RPLND, 62 had active EC in final pathology. Adjuvant chemotherapy (2 cycles of EP or BEP) was given to 5 patients. After a median follow-up of 37.7 months, 10 recurred, with a recurrence-free survival (RFS) of 85.1%. Following induction chemotherapy for documented recurrence, 9 patients were disease-free, with 1 disease-related death. Disease-free survival (DFS) was 98.5%. There were no in-field recurrences in the primary RPLND group. Of the 75 patients who received chemotherapy, 25 required post-chemotherapy (PC) RPLND, which revealed either teratoma or necrosis, and no active cancer was found. One recurred and needed re-do RPLND. Five patients who achieved complete remission after chemotherapy recurred, requiring second-line and high-dose chemotherapy. The RFS was 92%, with a median follow-up of 34.1 months. DFS was 97.3%. Univariate analysis showed pre-orchiectomy AFP &gt;100 ng/mL (OR 7.6, 95% CI 1.6–54.9) and teratoma &gt;5% in the orchiectomy specimen (OR 4.1, 95% CI 1.3–13.2) were associated with the need for PC-RPLND, but no parameters were predictive in multivariate analysis. Conclusions: Primary RPLND achieved complete remission as a single treatment modality in 85% of patients, compared to 67% for chemotherapy. Primary RPLND may reduce treatment burden in early-stage II ECP NSGCT in well-selected patients.